<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449578</url>
  </required_header>
  <id_info>
    <org_study_id>223HV103</org_study_id>
    <nct_id>NCT01449578</nct_id>
  </id_info>
  <brief_title>Dexpramipexole SAD/MAD Study</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled Ascending Dose Study of the Safety and Pharmacokinetics of Dexpramipexole in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knopp Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Knopp Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single
      doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID
      dexpramipexole in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preclinical and clinical data to date support the exploration of doses of dexpramipexole
      higher than 150 mg twice daily for their effectiveness in slowing the progression of ALS.
      Exploration of doses of dexpramipexole higher than 150 mg twice daily is justified by
      preclinical and clinical data that suggest that higher doses could potentially be more
      effective in slowing the progression of ALS than the dose of dexpramipexole currently being
      explored in Phase 3 studies (150 mg twice daily).

      This is a Phase 1, single-center, blinded, randomized, placebo controlled, ascending-dose
      study consisting of 2 parts; Part A (single-ascending dose [SAD]) and Part B (multiple
      ascending dose [MAD]). The study will explore safety, tolerability, and pharmacokinetics of
      single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300
      mg BID dexpramipexole in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability based on medical review of adverse events &amp; results of vital sign measurements, electrocardiogram (ECGs), physical examinations and clinical laboratory tests.</measure>
    <time_frame>Change from baseline to 11 Days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dexpramipexole pharmacokinetics time frame in plasma</measure>
    <time_frame>pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Part A, Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (SAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole single dose placebo (SAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (SAD Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole single dose placebo (SAD Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (SAD Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Treatment 3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole single dose placebo (SAD Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole multiple dose (MAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole multiple dose placebo (MAD Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole multiple dose (MAD Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Treatment 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexpramipexole multiple dose placebo (MAD Dose 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole</intervention_name>
    <description>Oral Tablet at varying doses</description>
    <arm_group_label>Part A, Treatment 3</arm_group_label>
    <arm_group_label>Part B, Treatment 2</arm_group_label>
    <arm_group_label>Part A, Treatment 1</arm_group_label>
    <arm_group_label>Part B, Treatment 1</arm_group_label>
    <arm_group_label>Part A, Treatment 2</arm_group_label>
    <other_name>BIIB050</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpramipexole Placebo</intervention_name>
    <description>Oral tablet at varying doses</description>
    <arm_group_label>Part B, Treatment 2 placebo</arm_group_label>
    <arm_group_label>Part A, Treatment 1 placebo</arm_group_label>
    <arm_group_label>Part A, Treatment 2 placebo</arm_group_label>
    <arm_group_label>Part A, Treatment 3 placebo</arm_group_label>
    <arm_group_label>Part B, Treatment 1 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent.

          -  Adult males/females aged 18 to 55 years inclusive and between 19 and 30 kg/m2 body
             mass index (BMI), inclusive at screening.

          -  Subjects who are healthy as determined by prestudy medical history, physical
             examination and 12-lead ECG.

          -  Subjects of childbearing potential must practice effective contraception during the
             study and be willing and able to continue contraception for 1 month (females) or 3
             months (males) after their last dose of study treatment.

          -  Normal systemic blood pressure defined as a systolic blood pressure of 90 to 140 mmHg
             and a diastolic blood pressure of 50 to 90 mmHg.

        Exclusion Criteria:

          -  History of cardiovascular disease (e.g., hypertension, arrhythmia, heart failure, Long
             QT Syndrome, or other conditions/diseases causing prolongation of the QT/QTc
             interval).

          -  A prolongation of QT/QTc interval (e.g., repeated demonstration of a QT/QTc interval
             &gt;450 ms before study treatment administration) at screening, admission or pre-dose on
             Day 1.

          -  Any clinically important abnormalities in resting ECG that may interfere with the
             interpretation of QTc interval changes at screening, admission or pre-dose on Day 1.

          -  Prior exposure to dexpramipexole.

          -  Treatment with pramipexole or any dopamine agonist within 1 year.

          -  Treatment with another investigational drug or approved therapy for investigational
             use within 30 days, or 5 half-lives (whichever is longer), or in follow up for any
             other drug, biologic, or device study.

          -  Currently active infection or serious infection (e.g., pneumonia, septicemia) within
             the 2 months prior to Day -2 as determined by the Investigator.

          -  Female subjects who are pregnant, currently breastfeeding, or attempting to conceive
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

